Healthcare
RetinalGenix Technologies Inc.(RTGN)
Live Price
Offline$4.00
+0.00% today
1Y Change
-20.32%
Window
Jun 20, 2025 โ Jun 4, 2026
- Market Cap
- $80.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +45.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RetinalGenix Technologies Inc. (RTGN) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $4.00 and down 20.3% across the available one-year price window (Jun 20, 2025 โ Jun 4, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +45.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +45.8%, free cash flow +24.7% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines RTGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Sep 30, 2023, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +45.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 Sep 30, 2023 | โ | +0.0% | +0.0% | -29.5% |
2023 Jun 30, 2023 | โ | +0.0% | +0.0% | -29.5% |
2023 Mar 31, 2023 | โ | +0.0% | +0.0% | -29.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RTGN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RTGN Max Drawdown
-36.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RTGN and SPY.
Company Overview
RetinalGenix Technologies Inc.
Other OTC
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
- Leadership
- Jerry Katzman
- IPO Date
- Feb 24, 2022
- Street Address
- 1450 North Mcdowell Boulevard
- Mailing
- Apollo Beach, CA, 94954
- Region
- Apollo Beach, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 578 9583
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +45.8%
- Free Cash Flow
- +24.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 119.6%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.